3/26
09:44 am
ifrx
InflaRx (NASDAQ: IFRX) had its price target raised by analysts at Guggenheim from $7.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
InflaRx (NASDAQ: IFRX) had its price target raised by analysts at Guggenheim from $7.00 to $10.00. They now have a "buy" rating on the stock.
3/21
08:09 am
ifrx
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/20
07:30 am
ifrx
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
Low
Report
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
3/7
12:54 pm
ifrx
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/7
09:13 am
ifrx
InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting [Yahoo! Finance]
Medium
Report
InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting [Yahoo! Finance]
3/7
08:00 am
ifrx
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
Medium
Report
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
2/28
09:07 am
ifrx
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting [Yahoo! Finance]
Low
Report
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting [Yahoo! Finance]
2/28
09:00 am
ifrx
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
Low
Report
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
2/25
07:30 am
ifrx
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
Medium
Report
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
2/18
04:01 pm
ifrx
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Low
Report
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
2/13
09:45 pm
ifrx
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
High
Report
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
2/13
06:07 pm
ifrx
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
High
Report
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants [Yahoo! Finance]
2/13
04:01 pm
ifrx
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
High
Report
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
1/23
07:30 am
ifrx
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
Medium
Report
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
1/16
07:32 am
ifrx
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
1/15
12:30 pm
ifrx
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
Low
Report
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
1/7
08:35 am
ifrx
InflaRx Announces Participation in January Events in San Francisco [Yahoo! Finance]
High
Report
InflaRx Announces Participation in January Events in San Francisco [Yahoo! Finance]
1/7
07:30 am
ifrx
InflaRx Announces Participation in January Events in San Francisco
High
Report
InflaRx Announces Participation in January Events in San Francisco